Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,043 Million (Small Cap)
15.00
NA
1.64%
0.11
9.93%
1.52
Revenue and Profits:
Net Sales:
537 Million
(Quarterly Results - Mar 2026)
Net Profit:
59 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.08%
0%
-10.08%
6 Months
-10.36%
0%
-10.36%
1 Year
14.46%
0%
14.46%
2 Years
4.61%
0%
4.61%
3 Years
-39.2%
0%
-39.2%
4 Years
-50.44%
0%
-50.44%
5 Years
-60.03%
0%
-60.03%
Shanghai Kindly Enterprises Development Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.06%
EBIT Growth (5y)
-6.38%
EBIT to Interest (avg)
13.88
Debt to EBITDA (avg)
0.62
Net Debt to Equity (avg)
0.15
Sales to Capital Employed (avg)
0.73
Tax Ratio
9.39%
Dividend Payout Ratio
30.43%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
15.98%
ROE (avg)
14.78%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.48
EV to EBIT
18.03
EV to EBITDA
10.60
EV to Capital Employed
1.42
EV to Sales
1.90
PEG Ratio
1.58
Dividend Yield
1.72%
ROCE (Latest)
7.86%
ROE (Latest)
9.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
536.70
577.20
-7.02%
Operating Profit (PBDIT) excl Other Income
63.20
89.60
-29.46%
Interest
3.80
4.00
-5.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
59.30
47.00
26.17%
Operating Profit Margin (Excl OI)
117.70%
85.10%
3.26%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -7.02% vs -3.20% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 26.17% vs -39.12% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,284.30
2,238.20
2.06%
Operating Profit (PBDIT) excl Other Income
423.50
382.30
10.78%
Interest
18.50
23.60
-21.61%
Exceptional Items
1.00
-1.90
152.63%
Consolidate Net Profit
261.10
233.80
11.68%
Operating Profit Margin (Excl OI)
115.80%
94.70%
2.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 2.06% vs -7.83% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 11.68% vs -15.41% in Dec 2024
About Shanghai Kindly Enterprises Development Group Co., Ltd. 
Shanghai Kindly Enterprises Development Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






